CompletedPhase 1NCT02885506

A FIH Study to Investigate the Safety, Tolerability and PK of P218

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medicines for Malaria Venture
Principal Investigator
Emilie Rossignol, PhD
Medicines for Malaria Venture
Intervention
Oral administration of P218 capsules(drug)
Enrollment
64 target
Eligibility
18-45 years · All sexes
Timeline
20162017

Study locations (1)

Collaborators

Richmond Pharmacology Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02885506 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials